Dual-targeted disease-modifying therapies for osteoarthritis

Affiliations

¹ Guangxi Engineering Center in Biomedical Materials for Tissue and Organ Regeneration, Collaborative Innovation Centre of Regenerative Medicine and Medical BioResource Development and Application Co-constructed By the Province and Ministry, Department of Orthopedics Trauma and Hand Surgery, Guangxi Key Laboratory of Regenerative Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.
² Experimental Center of BIOQGene, YuanDong International Academy of Life Sciences, Hong Kong Special Administrative Region, China; Systems Biology Research Center, Biology Institute, Guangxi Academy of Sciences, Nanning, China.
³ Guangxi Engineering Center in Biomedical Materials for Tissue and Organ Regeneration, Collaborative Innovation Centre of Regenerative Medicine and Medical BioResource Development and Application Co-constructed By the Province and Ministry, Department of Orthopedics Trauma and Hand Surgery, Guangxi Key Laboratory of Regenerative Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China. Electronic address: gxzj1962@163.com.

Comment

Li Zheng et al. Lancet. 2024.

. 2024 Jun 15;403(10444):2591.

doi: 10.1016/S0140-6736(24)00475-6.

¹ Guangxi Engineering Center in Biomedical Materials for Tissue and Organ Regeneration, Collaborative Innovation Centre of Regenerative Medicine and Medical BioResource Development and Application Co-constructed By the Province and Ministry, Department of Orthopedics Trauma and Hand Surgery, Guangxi Key Laboratory of Regenerative Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.
² Experimental Center of BIOQGene, YuanDong International Academy of Life Sciences, Hong Kong Special Administrative Region, China; Systems Biology Research Center, Biology Institute, Guangxi Academy of Sciences, Nanning, China.
³ Guangxi Engineering Center in Biomedical Materials for Tissue and Organ Regeneration, Collaborative Innovation Centre of Regenerative Medicine and Medical BioResource Development and Application Co-constructed By the Province and Ministry, Department of Orthopedics Trauma and Hand Surgery, Guangxi Key Laboratory of Regenerative Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China. Electronic address: gxzj1962@163.com.

No abstract available

Comment on

Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study.
Eckstein F, Hochberg MC, Guehring H, Moreau F, Ona V, Bihlet AR, Byrjalsen I, Andersen JR, Daelken B, Guenther O, Ladel C, Michaelis M, Conaghan PG. Eckstein F, et al. Ann Rheum Dis. 2021 Aug;80(8):1062-1069. doi: 10.1136/annrheumdis-2020-219181. Epub 2021 May 7. Ann Rheum Dis. 2021. PMID: 33962962 Free PMC article. Clinical Trial.
Na_v1.7 as a chondrocyte regulator and therapeutic target for osteoarthritis.
Fu W, Vasylyev D, Bi Y, Zhang M, Sun G, Khleborodova A, Huang G, Zhao L, Zhou R, Li Y, Liu S, Cai X, He W, Cui M, Zhao X, Hettinghouse A, Good J, Kim E, Strauss E, Leucht P, Schwarzkopf R, Guo EX, Samuels J, Hu W, Attur M, Waxman SG, Liu CJ. Fu W, et al. Nature. 2024 Jan;625(7995):557-565. doi: 10.1038/s41586-023-06888-7. Epub 2024 Jan 3. Nature. 2024. PMID: 38172636 Free PMC article.